FNY Investment Advisers’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-31,500
Closed -$1.7M 797
2025
Q4
$1.7M Buy
31,500
+29,004
+1,162% +$1.4M 0.48% 43
2025
Q3
$112K Buy
2,496
+886
+55% +$41.4K 0.04% 363
2025
Q2
$74K Sell
1,610
-1,500
-48% -$73.6K 0.03% 334
2025
Q1
$189K Sell
3,110
-9,320
-75% -$543K 0.12% 148
2024
Q4
$703K Buy
12,430
+12,360
+17,657% +$691K 0.36% 63
2024
Q3
$3K Hold
70
﹤0.01% 579
2024
Q2
$2K Hold
70
﹤0.01% 393
2024
Q1
$3 Sell
70
-5,780
-99% -$294K ﹤0.01% 547
2023
Q4
$300K Buy
5,850
+5,780
+8,257% +$303K 0.33% 65
2023
Q3
$4K Buy
70
+20
+40% +$1.23K ﹤0.01% 470
2023
Q2
$3K Hold
50
﹤0.01% 409
2023
Q1
$3K Hold
50
﹤0.01% 428
2022
Q4
$3K Buy
+50
New +$3.77K ﹤0.01% 390
2022
Q3
Sell
-35
Closed -$2K 665
2022
Q2
$2K Buy
+35
New +$2.67K ﹤0.01% 566
2022
Q1
Sell
-70
Closed -$4K 750
2021
Q4
$4K Sell
70
-22,500
-100% -$1.32M ﹤0.01% 450
2021
Q3
$1.33M Buy
+22,570
New +$1.49M 0.62% 44
2021
Q1
Sell
-15,000
Closed -$930K 797
2020
Q4
$930K Buy
15,000
+12,500
+500% +$769K 0.25% 98
2020
Q3
$150K Buy
+2,500
New +$150K 0.06% 186

Other funds holding BMY

FNY Investment Advisers's BMY Position: Q1 2026 in Review

FNY Investment Advisers sold out of Bristol-Myers Squibb (BMY) in Q1 2026, closing a stake of 31,500 shares — an estimated $1.7M sold.

FNY Investment Advisers first reported a position in BMY in Q3 2020 and held it in 18 quarters. The position peaked at $1.7M in Q4 2025. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • FNY Investment Advisers reported no remaining Bristol-Myers Squibb position as of Q1 2026 after selling out during the quarter.
  • FNY Investment Advisers sold 31,500 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.7M.
  • FNY Investment Advisers first reported a position in Bristol-Myers Squibb in Q3 2020 and held it in 18 quarters.
  • FNY Investment Advisers's Bristol-Myers Squibb position peaked at $1.7M in Q4 2025.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on FNY Investment Advisers's 13F filing for Q1 2026, filed 15 Apr 2026.